| scholarly article | Q13442814 |
| P50 | author | María José Ortiz-Morales | Q85063745 |
| Antonio Rodriguez-Ariza | Q42767633 | ||
| P2093 | author name string | Barbara Manzanares-Martin | |
| Juan De la Haba-Rodriguez | |||
| Enrique Aranda-Aguilar | |||
| Javier Lopez-Gonzalez | |||
| Alberto Moreno-Vega | |||
| Beatriz Chia-Delgado | |||
| Cristina Morales-Estevez | |||
| Ignacio Porras-Quintela | |||
| Maria A Gomez-España | |||
| Maria T Cano-Osuna | |||
| Rafael Gonzalez-Fernandez | |||
| P2860 | cites work | Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. | Q45993730 |
| Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 | ||
| Apoptosis induction by trastuzumab: possible role of the core biopsy intervention | Q81280288 | ||
| Killer cell immunoglobulin-like receptor genes in patients with breast cancer | Q83821421 | ||
| KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population | Q84630125 | ||
| Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1 | Q24316372 | ||
| Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity | Q26773135 | ||
| NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy | Q26797345 | ||
| Effects of Peptide on NK cell-mediated MHC I recognition | Q26822893 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| KIR: diverse, rapidly evolving receptors of innate and adaptive immunity | Q28203441 | ||
| KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential | Q28203519 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors | Q28259065 | ||
| The KIR gene family: life in the fast lane of evolution | Q28296724 | ||
| Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. | Q29568902 | ||
| Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients | Q31115968 | ||
| KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy | Q33430704 | ||
| NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals | Q33829849 | ||
| Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression | Q35753686 | ||
| Interleukin 21: a key player in lymphocyte maturation | Q35978480 | ||
| Hanging in the balance. KIR and their role in disease. | Q36241147 | ||
| The Yin and Yang of HLA and KIR in human disease | Q36410540 | ||
| Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. | Q36552780 | ||
| Human natural killer cells | Q36787596 | ||
| Current perspective - trastuzumab | Q37337654 | ||
| Controlling natural killer cell responses: integration of signals for activation and inhibition | Q37404156 | ||
| Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. | Q37537926 | ||
| Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias | Q37576040 | ||
| The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). | Q37589671 | ||
| Activating killer cell Ig-like receptors in health and disease | Q37725657 | ||
| KIR and KIR ligand polymorphism: a new area for clinical applications? | Q38185422 | ||
| KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. | Q38950020 | ||
| Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. | Q40257828 | ||
| P304 | page(s) | 561 | |
| P577 | publication date | 2016-12-05 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors | |
| P478 | volume | 7 |
Search more.